Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. (ROIV) filed a Rule 144 notice disclosing a proposed sale of 611,079 shares of common stock, scheduled approximately 09/23/2025 through Charles Schwab & Co. The filing lists an aggregate market value of $9,129,520.26 and reports 682,881,743 shares outstanding. The shares were acquired as equity compensation on 01/20/2023 for services rendered. The filer also reported three recent sales by Eric Venker totaling 1,200,000 shares between 07/21/2025 and 09/19/2025 with combined gross proceeds shown. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) filed a Rule 144 notice disclosing a proposed sale of 611,079 shares of common stock, scheduled approximately 09/23/2025 through Charles Schwab & Co. The filing lists an aggregate market value of $9,129,520.26 and reports 682,881,743 shares outstanding. The shares were acquired as equity compensation on 01/20/2023 for services rendered. The filer also reported three recent sales by Eric Venker totaling 1,200,000 shares between 07/21/2025 and 09/19/2025 with combined gross proceeds shown. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) filed a Form 144 notifying a proposed sale of 316,182 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $4,741,054.24, scheduled approximately for 09/22/2025. The shares were reported acquired the same day via a stock option exercise and paid for in cash. The filing also discloses prior sales by Eric Venker totaling 883,818 shares across July–September 2025 with combined gross proceeds of $12,644,412.21. The notice includes the sellers representation there is no undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) filed a Form 144 notifying a proposed sale of 316,182 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $4,741,054.24, scheduled approximately for 09/22/2025. The shares were reported acquired the same day via a stock option exercise and paid for in cash. The filing also discloses prior sales by Eric Venker totaling 883,818 shares across July–September 2025 with combined gross proceeds of $12,644,412.21. The notice includes the sellers representation there is no undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) insider notice under Rule 144: This Form 144 reports a proposed sale of 100,000 common shares by a person for whose account the securities are to be sold, using Rockefeller Financial LLC as broker on 09/22/2025. The filing states an aggregate market value of $1,501,338.85 for the shares and notes there are 682,881,743 shares outstanding.
The shares were acquired the same day through an options exercise (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire. The filer also discloses two prior sales in the past three months: 100,000 shares sold on 08/20/2025 (gross proceeds $1,172,120.12) and 100,000 shares sold on 07/21/2025 (gross proceeds $1,151,941.91).
Roivant Sciences Ltd. (ROIV) insider notice under Rule 144: This Form 144 reports a proposed sale of 100,000 common shares by a person for whose account the securities are to be sold, using Rockefeller Financial LLC as broker on 09/22/2025. The filing states an aggregate market value of $1,501,338.85 for the shares and notes there are 682,881,743 shares outstanding.
The shares were acquired the same day through an options exercise (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire. The filer also discloses two prior sales in the past three months: 100,000 shares sold on 08/20/2025 (gross proceeds $1,172,120.12) and 100,000 shares sold on 07/21/2025 (gross proceeds $1,151,941.91).
Roivant Sciences Ltd. (ROIV) filing a Form 144 notifies an intended sale of 683,818 common shares via Morgan Stanley Smith Barney on 09/19/2025, with an aggregate market value reported as $10,220,412.21. The shares were acquired and paid for on 09/19/2025 through a stock option exercise with cash payment. The filer also reported three prior open-market sales by Eric Venker totaling 300,000 shares during June–August 2025 for combined gross proceeds of $3,452,000.00. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) filing a Form 144 notifies an intended sale of 683,818 common shares via Morgan Stanley Smith Barney on 09/19/2025, with an aggregate market value reported as $10,220,412.21. The shares were acquired and paid for on 09/19/2025 through a stock option exercise with cash payment. The filer also reported three prior open-market sales by Eric Venker totaling 300,000 shares during June–August 2025 for combined gross proceeds of $3,452,000.00. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Matthew Gline, listed as Director and CEO of Roivant Sciences Ltd. (ROIV), reported a purchase of 3,315 common shares on 09/18/2025 at a weighted average price of $15.07 per share. After this transaction the filing shows Mr. Gline beneficially owns 17,287,081 common shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Gline.
Matthew Gline, listed as Director and CEO of Roivant Sciences Ltd. (ROIV), reported a purchase of 3,315 common shares on 09/18/2025 at a weighted average price of $15.07 per share. After this transaction the filing shows Mr. Gline beneficially owns 17,287,081 common shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Gline.
Roivant Sciences Ltd. reported that its subsidiary Priovant Therapeutics achieved positive results in the Phase 3 VALOR study of brepocitinib in dermatomyositis, a serious autoimmune muscle disease. The company released a detailed press release and an investor presentation describing these Phase 3 results.
Roivant also scheduled a conference call and webcast at 8:00 a.m. E.D.T. on September 17, 2025 to discuss the VALOR data, and posted the related presentation on the investor relations section of its website. These materials are furnished as exhibits to the report, giving investors additional information on the study outcome.
Roivant Sciences Ltd. reported the results of shareholder votes demonstrating routine corporate governance outcomes. Shareholders re-elected the individuals named to serve as Class I directors to hold office until the annual general meeting following the fiscal year ending March 31, 2028. Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed in the proxy statement. The advisory vote tallied 316,651,402 votes in favor, 203,244,184 against and 64,550,276 abstentions; there were 44,227,813 broker non-votes reported. The filing includes the cover page interactive data file as an exhibit.
Roivant Sciences director Vivek Ramaswamy reported multiple open-market sales of the company's common shares on September 3–5, 2025. The Form 4 shows he disposed of 1,195,000 shares on 09/03/2025 at a weighted-average price of $12.50, 194,933 shares on 09/04/2025 at $12.92 weighted-average, and 385,816 shares on 09/05/2025 at $12.96 weighted-average, for total reported disposals of 1,775,749 shares. After these transactions he beneficially owns 35,508,359 shares directly and holds an additional 13,357,857 shares indirectly. Footnotes state the reported prices are weighted averages reflecting multiple transactions in specified price ranges, and the form is signed by an attorney-in-fact.
Roivant Sciences Ltd. reported that it has provided an update on the Graves’ Disease development program at its subsidiary, Immunovant, Inc. The company issued a press release and made it available as an exhibit, focusing on Immunovant’s proof-of-concept study in Graves’ Disease.
Roivant also posted an investor presentation covering the update on Immunovant’s Graves’ Disease proof-of-concept study on its investor relations website and scheduled a conference call and webcast to discuss remission data from Immunovant’s Graves’ Disease trial at 4:30 p.m. E.D.T. Both the press release and the presentation are included as exhibits to the report, while the website content itself is not incorporated.
Richard Pulik, identified as CFO and a director of Roivant Sciences Ltd. (ROIV), reported a disposition of 2,340 common shares on 08/28/2025 at a price of $11.94 per share. The filing states this sale represents a net settlement by the issuer to satisfy tax withholding obligations related to previously granted restricted stock units (RSUs). Following the reported transaction, Mr. Pulik beneficially owned 393,978 shares. The Form 4 was signed by an attorney-in-fact on 09/02/2025.